Bill Welch

Bill is a senior executive, business leader and entrepreneur in the precision medicine sector cutting across molecular diagnostics, genomics and targeted therapeutics. His interest and passion is in the consumerization of healthcare through precision therapeutics, genetics and digital health.

Prior to joining Illumina Ventures, Bill was CEO at Trovagene, a precision oncology therapeutics and genetics company capitalizing on circulating tumor DNA in urine. He was also president and CEO at Sequenom, a leading molecular diagnostics company specializing in clinical applications of whole genomic sequencing for the reproductive health and oncology markets. While there, Bill led the development and commercialization of the first non-invasive prenatal test (NIPT) for detecting and accurately measuring fetal genomic DNA in a mother’s blood and helped establish NIPT as the new global clinical standard for prenatal testing and a multibillion-dollar diagnostic market. Prior to Sequenom, he was chief commercial officer at Monogram Biosciences, a molecular immunology and oncology technology company. Bill entered the healthcare industry with Abbott Laboratories where he held progressive management positions in licensing, technology and therapeutics. He serves as a board member at Serimmune.

Bill has designed and launched products under a number of novel commercial healthcare models utilizing the US Food and Drug Administration’s regulatory approvals for NDA’s, PMA’s and 510 (k)’s and the Centers for Medicare & Medicaid Services for Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologist (CAP) certifications.

Bill has a Master of Business Administration from Harvard University and a Bachelor of Science in Chemical Engineering from the University of California, Berkeley.